The demonstration of the important role of the PI3K-Akt-mTOR pathway in pancreatic NET (PAN-NET) tumorigenesis [6] and the finding of an abnormal activation of mTOR—a serine/threonine protein kinase—in patients with PAN-NET [7] led to the use of the mTOR inhibitor everolimus for the treatment of pulmonary neuroendocrine tumors (PNTs) and PAN-NETs [8,9]. This evidence concerns the gene AKT1 and lung neuroendocrine neoplasm.